JP2011207882A5 - - Google Patents

Download PDF

Info

Publication number
JP2011207882A5
JP2011207882A5 JP2011075243A JP2011075243A JP2011207882A5 JP 2011207882 A5 JP2011207882 A5 JP 2011207882A5 JP 2011075243 A JP2011075243 A JP 2011075243A JP 2011075243 A JP2011075243 A JP 2011075243A JP 2011207882 A5 JP2011207882 A5 JP 2011207882A5
Authority
JP
Japan
Prior art keywords
seq
absent
antibody
administering
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011075243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011207882A (ja
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed filed Critical
Publication of JP2011207882A publication Critical patent/JP2011207882A/ja
Publication of JP2011207882A5 publication Critical patent/JP2011207882A5/ja
Withdrawn legal-status Critical Current

Links

JP2011075243A 2004-10-19 2011-03-30 アンジオポエチン−2特異的結合物質 Withdrawn JP2011207882A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US60/620,161 2004-10-19
US10/982,440 2004-11-04
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007538066A Division JP2008520188A (ja) 2004-10-19 2005-10-19 アンジオポエチン−2特異的結合物質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013190316A Division JP2014040428A (ja) 2004-10-19 2013-09-13 アンジオポエチン−2特異的結合物質

Publications (2)

Publication Number Publication Date
JP2011207882A JP2011207882A (ja) 2011-10-20
JP2011207882A5 true JP2011207882A5 (enExample) 2012-06-21

Family

ID=39608222

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007538066A Pending JP2008520188A (ja) 2004-10-19 2005-10-19 アンジオポエチン−2特異的結合物質
JP2011075243A Withdrawn JP2011207882A (ja) 2004-10-19 2011-03-30 アンジオポエチン−2特異的結合物質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007538066A Pending JP2008520188A (ja) 2004-10-19 2005-10-19 アンジオポエチン−2特異的結合物質

Country Status (10)

Country Link
JP (2) JP2008520188A (enExample)
CN (1) CN101495513B (enExample)
BR (1) BRPI0518209A (enExample)
EA (1) EA011866B1 (enExample)
IL (1) IL182279A0 (enExample)
MA (1) MA29015B1 (enExample)
MX (1) MX2007004247A (enExample)
RU (2) RU2404992C2 (enExample)
SG (1) SG156668A1 (enExample)
ZA (1) ZA200704020B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
EP2760471B9 (en) * 2011-09-30 2017-07-19 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
ES2687968T3 (es) * 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
SG11202108832XA (en) * 2019-02-25 2021-09-29 Pharmabcine Inc Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2199804T3 (es) * 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
WO2001097850A2 (en) * 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003030883A1 (en) * 2001-10-12 2003-04-17 Kosmos Pharma Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2

Similar Documents

Publication Publication Date Title
JP2011207882A5 (enExample)
CA2583910A1 (en) Angiopoietin-2 specific binding agents
JP2022101693A5 (enExample)
JP2013502913A5 (enExample)
JP2014511179A5 (enExample)
JP2020504076A5 (enExample)
JP2013506428A5 (enExample)
JP2020500003A5 (enExample)
JP2009225799A5 (enExample)
JP2017507652A5 (enExample)
RU2010132956A (ru) Ангиопоэтин-2-специфические связывающие агенты
RU2015141428A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2014503202A (ja) TNF−α結合性タンパク質
JP2014527814A5 (enExample)
JP2019527194A5 (enExample)
JP2019505527A5 (enExample)
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2012530487A5 (enExample)
JP2013519367A5 (enExample)
JPWO2021139777A5 (enExample)
JP2010527939A5 (enExample)
JP2020533965A5 (enExample)
JP2020522488A5 (enExample)